Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme Patients
Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that its partner CA…